New Safety Information | Pharmacovigilance .: HALMED

Direct healthcare professional communication on the importance of following instructions for use of Genotropin (somatropin) to mitigrate potential defect in pre-filled pen device

04.01.2016

Pfizer Croatia d.o.o., in agreement with the Agency for Medicinal Products and Medical Devices (HALMED) has informed healthcare professionals on the importance of following instructions for use of Genotropin 5,3 mg powder and solvent for solution for injection and Genotropin 12 mg powder and solvent for solution for injection (somatropin) to mitigrate potential defect in pre-filled pen device.

Direct healthcare professional communication on the new safety information related to the hepatic safety of Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir)

04.01.2016

AbbVie d.o.o., in agreement with the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) and the European Medicines Agency (EMA), has informed healthcare professionals of important new safety information related to the hepatic safety of Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir).

Pharmacovigilance

SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis

CMDh News – January 2016

CHMP News – January 2016

Direct healthcare professional communication on the new recommendations to minimise the risk of intestinal obstruction related to use of TachoSil (human fibrinogen/human thrombin)

Direct healthcare professional communication on the risks related to the effects of fingolimod (Gilenya) on the immune system

PRAC News – January 2016

Direct healthcare professional communication on the restriction of indication for treatment with Tarceva (erlotinib)

Direct healthcare professional communication on the importance of following instructions for use of Genotropin (somatropin) to mitigrate potential defect in pre-filled pen device

Direct healthcare professional communication on the new safety information related to the hepatic safety of Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir)